Contract manufacturer National Resilience and Eli Lilly are pouring another $750 million into a manufacturing operation in Ohio, aiming to shore up the U.S. supply of injectable diabetes and obesity medicines.
The joint investment, announced this week, expands Resilience’s advanced manufacturing in the Cincinnati region to assemble Lilly’s KwikPen injectable device. Full operations are expected in early 2027, and the expansion will create at least 400 new jobs — pushing Resilience’s Ohio headcount past 1,400. The company, headquartered in Blue Ash, Ohio, already runs two facilities in the region employing close to 1,000 people.
Why now
Demand for injectable diabetes and weight-loss treatments has strained supply across the industry. The two companies say their partnership, established in 2023, has already produced more than 150 million doses in vial and pre-filled-syringe formats for U.S. patients; the new money scales up the device-assembly side of that pipeline.
Part of a reshoring push
The deal lands amid a broader drive to bring more drug production back to the United States. Resilience chief executive William Marth said the investment shows how “trusted partnerships, operational excellence, and disciplined execution can strengthen America’s medicine supply,” while Lilly’s manufacturing chief stressed that scaling complex programs demands “proven technical capability” and “an uncompromising commitment to quality.”